We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current YIHCF market cap is 359.57M. The company's latest EPS is CNY 3.0479 and P/E is 0.18.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 6.22B | 2.35B | 913.79M | 3.74B | 6.29B |
| Operating Income | 2.44B | 698.03M | -466.75M | 889.46M | 2.39B |
| Net Income | 1.92B | 839.46M | -587.65M | 76.6M | 1.99B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 9.91B | 9.56B | 10.54B | 11.89B | 12.74B |
| Total Liabilities | 5.29B | 4.46B | 4.52B | 5.82B | 4.81B |
| Total Equity | 4.62B | 5.1B | 6.02B | 6.07B | 7.94B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 1.79B | 1.3B | -662.51M | 1.7B | 1.67B |
| Investing | -1.71B | -2.09B | -439.11M | -1.12B | 554.57M |
| Financing | 2.1B | 64.63M | 187.48M | -787.03M | -1.48B |
| Market Cap | 359.57M |
| Price to Earnings Ratio | 0.18 |
| Price to Sales Ratio | 0.06 |
| Price to Cash Ratio | 0.21 |
| Price to Book Ratio | 0.05 |
| Dividend Yield | - |
| Shares Outstanding | 653.77M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Yichang Hec Changjiang Pharmaceutical Co Ltd (PK) |
| Address |
no.38 binjiang road yichang, hubei |
| Website | https://www.hec-changjiang.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
